{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:12Z","timestamp":1794017232553,"version":"4.8.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA246182"],"award-info":[{"award-number":["R01CA246182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["R21CA273779"],"award-info":[{"award-number":["R21CA273779"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapeutic options, where platinum-based chemotherapy such as carboplatin serves as a cornerstone of treatment. Despite initial responses, the rapid emergence of acquired resistance remains a major clinical barrier. Understanding the molecular adaptations that drive platinum resistance is essential to develop strategies to restore sensitivity and identify alternative vulnerabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated four isogenic patient-derived xenograft (PDX) pairs (WHIM30, BCM\u20112147, BCM\u20113887, BCM\u20117482) through serial carboplatin exposure to model acquired resistance in TNBC. Bulk RNA sequencing, immunohistochemistry, and histopathological analyses were performed to define transcriptomic and phenotypic changes associated with resistance. Synergistic therapeutic combinations were identified using high-throughput drug screening in carboplatin-resistant (CR) PDX-derived models, followed by in vivo validation in NSG mice. Tumor growth and survival were assessed using mixed-effects modeling, two-way ANOVA, and Welch\u2019s student t-test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The resulting isogenic PDX pairs captured both convergent and model-specific adaptations to carboplatin. CR tumors demonstrated heterogeneous activation of DNA damage repair pathways, including restoration of BRCA1-dependent homologous recombination (BCM\u20112147, WHIM30) and compensatory upregulation of mismatch repair (BCM\u20113887). In the BRCA1-mutant BCM\u20117482 model, resistance correlated with HORMAD1 upregulation, suggesting an alternative HRD-associated mechanism. Morphologically, BCM\u20117482CR tumors exhibited a significant increase in nuclear size compared to their sensitive counterpart (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                    <jats:p>Drug screening identified mTOR pathway inhibition as a recurrent vulnerability across CR models. Sacituzumab govitecan (SG) combined with Everolimus produced robust synergy in vitro and superior tumor control in vivo compared to single agents in both WHIM30CR and BCM\u20112147CR. A second combination, Everolimus\u2009+\u2009Selinexor (KPT\u2011330), also reduced tumor burden, achieving statistical significance in an expanded WHIM30CR cohort and suppressing metastatic progression in the intrinsically resistant WHIM2 model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Isogenic PDX models of TNBC provide a powerful platform to define molecular mechanisms of acquired carboplatin resistance and uncover actionable therapeutic strategies. Our findings reveal multiple adaptive routes to platinum resistance, including restoration of homologous recombination and activation of alternative DNA repair programs. Synergistic interactions between SG and mTOR inhibition offer a promising avenue for overcoming resistance, supporting further clinical investigation of these combinations in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03636-9","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:34:38Z","timestamp":1770078878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Julia E.","family":"Altman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dashti-Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Zboril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Myrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Olex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail G.","family":"Dozmorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-8418","authenticated-orcid":false,"given":"J. Chuck","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"6","key":"3636_CR1","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"key":"3636_CR2","doi-asserted-by":"publisher","unstructured":"Ma J, Jemal A. Breast Cancer Statistics. In: Ahmad A, editor. Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. New York, NY: Springer; 2013. pp. 1\u201318. Available from: https:\/\/doi.org\/10.1007\/978-1-4614-5647-6_1. [cited 2023 Dec 7]","DOI":"10.1007\/978-1-4614-5647-6_1"},{"issue":"1","key":"3636_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3636_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41598-020-58438-0","volume":"10","author":"TH Turner","year":"2020","unstructured":"Turner TH, Alzubi MA, Harrell JC. Identification of synergistic drug combinations using breast cancer patient-derived xenografts. Sci Rep. 2020;10(1):1493.","journal-title":"Sci Rep"},{"issue":"12","key":"3636_CR5","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.3390\/cancers15123179","volume":"15","author":"EK Zboril","year":"2023","unstructured":"Zboril EK, Grible JM, Boyd DC, Hairr NS, Leftwich TJ, Esquivel MF, et al. Stratification of Tamoxifen synergistic combinations for the treatment of ER\u2009+\u2009Breast cancer. Cancers. 2023;15(12):3179.","journal-title":"Cancers"},{"key":"3636_CR6","doi-asserted-by":"publisher","unstructured":"He L, Kulesskiy E, Saarela J, Turunen L, Wennerberg K, Aittokallio T et al. Methods for high-throughput drug combination screening and synergy scoring. Cancer Syst Biol Methods Protoc. 2018;1711:351\u201398. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_17","DOI":"10.1007\/978-1-4939-7493-1_17"},{"key":"3636_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fphy.2019.00158","volume":"7","author":"GF Murray","year":"2019","unstructured":"Murray GF, Turner TH, Guest D, Leslie KA, Alzubi MA, Radhakrishnan SK, et al. QPI allows in vitro drug screening of triple negative breast cancer PDX tumors and fine needle biopsies. Front Phys. 2019;7:158.","journal-title":"Front Phys"},{"issue":"5","key":"3636_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/cancers15051582","volume":"15","author":"DC Boyd","year":"2023","unstructured":"Boyd DC, Zboril EK, Olex AL, Leftwich TJ, Hairr NS, Byers HA, et al. Discovering synergistic compounds with BYL-719 in PI3K overactivated Basal-like PDXs. Cancers. 2023;15(5):1582.","journal-title":"Cancers"},{"issue":"1","key":"3636_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","volume":"17","author":"RS Go","year":"1999","unstructured":"Go RS, Adjei AA. Review of the comparative Pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409\u2013409.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3636_CR10","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.tranon.2021.101235","volume":"14","author":"NS Rashid","year":"2021","unstructured":"Rashid NS, Hairr NS, Murray G, Olex AL, Leftwich TJ, Grible JM, et al. Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer. Transl Oncol. 2021;14(12):101235.","journal-title":"Transl Oncol"},{"key":"3636_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10549-018-4748-4","volume":"170","author":"TH Turner","year":"2018","unstructured":"Turner TH, Alzubi MA, Sohal SS, Olex AL, Dozmorov MG, Harrell JC. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. Breast Cancer Res Treat. 2018;170:221\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"3636_CR12","unstructured":"Bd BPYCFV et al. C, R J, X S,. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO J. 2021;40(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33950524\/. [cited 2022 Aug 24]"},{"issue":"1","key":"3636_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","volume":"16","author":"SJ Isakoff","year":"2010","unstructured":"Isakoff SJ. Triple negative breast cancer: role of specific chemotherapy agents. Cancer J Sudbury Mass. 2010;16(1):53\u201361.","journal-title":"Cancer J Sudbury Mass"},{"issue":"8","key":"3636_CR14","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"3636_CR15","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.pmatsci.2023.101070","volume":"134","author":"X Kong","year":"2023","unstructured":"Kong X, Qi Y, Wang X, Jiang R, Wang J, Fang Y, et al. Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer. Prog Mater Sci. 2023;134:101070.","journal-title":"Prog Mater Sci"},{"issue":"5","key":"3636_CR16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1021\/cr068207j","volume":"107","author":"Y Jung","year":"2007","unstructured":"Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107(5):1387\u2013407.","journal-title":"Chem Rev"},{"issue":"18","key":"3636_CR17","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.4161\/cc.8.18.9624","volume":"8","author":"S Cruet-Hennequart","year":"2009","unstructured":"Cruet-Hennequart S, Villalan S, Kaczmarczyk A, O\u2019Meara E, Sokol AM, Carty MP. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle. 2009;8(18):3043\u201354.","journal-title":"Cell Cycle"},{"issue":"1","key":"3636_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","volume":"63","author":"DJ Stewart","year":"2007","unstructured":"Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12\u201331.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"3636_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3816\/CBC.2001.n.022","volume":"2","author":"M Mart\u00edn","year":"2001","unstructured":"Mart\u00edn M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer. 2001;2(3):190\u2013208.","journal-title":"Clin Breast Cancer"},{"issue":"4\u20135","key":"3636_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.drup.2004.08.002","volume":"7","author":"RP Wernyj","year":"2004","unstructured":"Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the achilles\u2019 heel. Drug Resist Updat. 2004;7(4\u20135):227\u201332.","journal-title":"Drug Resist Updat"},{"key":"3636_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","volume":"50","author":"GF de Sousa","year":"2014","unstructured":"de Sousa GF, Wlodarczyk SR, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz J Pharm Sci. 2014;50:693\u2013701.","journal-title":"Braz J Pharm Sci"},{"issue":"9","key":"3636_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge. Cells. 2019;8(9):957.","journal-title":"Cells"},{"issue":"6","key":"3636_CR23","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, Jovanovi\u0107 B, Chen X, Estrada MV, Johnson KN, Shyr Y et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Sapino A, editor. PLOS ONE. 2016;11(6):e0157368.","journal-title":"PLOS ONE"},{"issue":"7","key":"3636_CR24","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"issue":"8","key":"3636_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1586\/era.10.50","volume":"10","author":"A Constantinidou","year":"2010","unstructured":"Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010;10(8):1197\u2013213.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6127","key":"3636_CR26","first-page":"1546","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer Genome Landscapes Sci. 2013;339(6127):1546\u201358.","journal-title":"Cancer Genome Landscapes Sci"},{"issue":"1","key":"3636_CR27","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","volume":"12","author":"BD Lehmann","year":"2021","unstructured":"Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276.","journal-title":"Nat Commun"},{"issue":"5","key":"3636_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/jcmm.17124","volume":"26","author":"Y Li","year":"2022","unstructured":"Li Y, Kong X, Wang Z, Xuan L. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. J Cell Mol Med. 2022;26(5):1351\u201362.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"3636_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3390\/cells9081751","volume":"9","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, Kuznicki J. Biological and medical importance of cellular heterogeneity Deciphered by single-cell RNA sequencing. Cells. 2020;9(8):1751.","journal-title":"Cells"},{"issue":"10","key":"3636_CR30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/1615-9861(200110)1:10<1216::AID-PROT1216>3.0.CO;2-P","volume":"1","author":"H Hondermarck","year":"2001","unstructured":"Hondermarck H, Vercoutter-Edouart A, R\u00e9villion F, Lemoine J, El\u2010Yazidi\u2010Belkoura I, Nurcombe V, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteom Int Ed. 2001;1(10):1216\u201332.","journal-title":"Proteom Int Ed"},{"issue":"1","key":"3636_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cbpa.2003.12.009","volume":"8","author":"ON Jensen","year":"2004","unstructured":"Jensen ON. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol. 2004;8(1):33\u201341.","journal-title":"Curr Opin Chem Biol"},{"key":"3636_CR32","doi-asserted-by":"crossref","first-page":"117793221989905","DOI":"10.1177\/1177932219899051","volume":"14","author":"I Subramanian","year":"2020","unstructured":"Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data Integration, Interpretation, and its application. Bioinforma Biol Insights. 2020;14:1177932219899051.","journal-title":"Bioinforma Biol Insights"},{"issue":"8","key":"3636_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and Long-Term survival in patients with Triple-Negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3636_CR34","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/s41598-023-32568-7","volume":"13","author":"MG Dozmorov","year":"2023","unstructured":"Dozmorov MG, Marshall MA, Rashid NS, Grible JM, Valentine A, Olex AL, et al. Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft. Sci Rep. 2023;13(1):5420.","journal-title":"Sci Rep"},{"key":"3636_CR35","doi-asserted-by":"publisher","first-page":"101901","DOI":"10.1016\/j.tranon.2024.101901","volume":"42","author":"A Kar","year":"2024","unstructured":"Kar A, Agarwal S, Singh A, Bajaj A, Dasgupta U. Insights into molecular mechanisms of chemotherapy resistance in cancer. Transl Oncol. 2024;42:101901.","journal-title":"Transl Oncol"},{"issue":"10","key":"3636_CR36","doi-asserted-by":"publisher","first-page":"e70044","DOI":"10.1002\/ctm2.70044","volume":"14","author":"JE Altman","year":"2024","unstructured":"Altman JE, Olex AL, Zboril EK, Walker CJ, Boyd DC, Myrick RK, et al. Single-cell transcriptional atlas of human breast cancers and model systems. Clin Transl Med. 2024;14(10):e70044.","journal-title":"Clin Transl Med"},{"issue":"19","key":"3636_CR37","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047\u20138.","journal-title":"Bioinformatics"},{"key":"3636_CR38","unstructured":"Andrews S. FastQC: a quality control tool for high through-put sequence data. 2018. Available from: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/. [cited 2024 Oct 9]"},{"key":"3636_CR39","unstructured":"10x Genomics. Cell Ranger Secondary Analysis Outputs - Official 10x Genomics Support. Available from: https:\/\/www.10xgenomics.com\/support\/software\/cell-ranger\/latest\/analysis\/outputs\/cr-outputs-secondary-analysis. [cited 2024 Feb 27]."},{"issue":"13","key":"3636_CR40","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573\u201387.","journal-title":"Cell"},{"issue":"1","key":"3636_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1123-2","volume":"21","author":"MA Alzubi","year":"2019","unstructured":"Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, et al. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Res. 2019;21(1):1\u201315.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3636_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10\u20132.","journal-title":"EMBnet J"},{"issue":"1","key":"3636_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"key":"3636_CR44","first-page":"0","volume":"2","author":"DM Gendoo","year":"2015","unstructured":"Gendoo DM, Ratanasirigulchai N, Schr\u00f6der M, Pare L, Parker JS, Prat A, et al. Genefu: a package for breast cancer gene expression analysis. R Pack Age Version. 2015;2:0.","journal-title":"R Pack Age Version"},{"issue":"2","key":"3636_CR45","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of samtools and BCFtools. GigaScience. 2021;10(2):giab008.","journal-title":"GigaScience"},{"issue":"14","key":"3636_CR46","first-page":"2076","volume":"30","author":"V Obenchain","year":"2014","unstructured":"Obenchain V, Lawrence M, Carey V, Gogarten S, Shannon P, Morgan M. VariantAnnotation: a bioconductor package for exploration and annotation of genetic variants. Bioinf. 2014;30(14):2076\u20138.","journal-title":"Bioinf"},{"issue":"2","key":"3636_CR47","doi-asserted-by":"publisher","first-page":"gkaf018","DOI":"10.1093\/nar\/gkaf018","volume":"53","author":"Y Chen","year":"2025","unstructured":"Chen Y, Chen L, Lun ATL, Baldoni PL, Smyth GK. EdgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Res. 2025;53(2):gkaf018.","journal-title":"Nucleic Acids Res"},{"key":"3636_CR48","unstructured":"fiji\/fiji. Fiji. 2025. Available from: https:\/\/github.com\/fiji\/fiji.\u00a0[cited 2025 Aug 27]"},{"issue":"24","key":"3636_CR49","first-page":"e3465","volume":"20","author":"AR Crowe","year":"2019","unstructured":"Crowe AR, Yue W. Semi-quantitative determination of protein expression usingimmunohistochemistry staining and analysis. Bio-Protoc. 2019;20(24):e3465.","journal-title":"Bio-Protoc"},{"key":"3636_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. LmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1\u201326.","journal-title":"J Stat Softw"},{"key":"3636_CR51","unstructured":"The NExT Screening Libraries. (Pre-plated Copies Available) | Discovery | NExT Resources | NExT. Available from: https:\/\/next.cancer.gov\/discoveryresources\/resources_ndl.htm#oncology_interrogation_tools.\u00a0[cited 2024 Apr 1]"},{"key":"3636_CR52","unstructured":"CellTiter-Glo\u00ae. Luminescent Cell Viability Assay Protocol. Available from: https:\/\/www.promega.com\/resources\/protocols\/technical-bulletins\/0\/celltiter-glo-luminescent-cell-viability-assay-protocol\/.\u00a0[cited 2025 July 29]"},{"issue":"W1","key":"3636_CR53","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3636_CR54","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3636_CR55","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/CAD.0000000000000751","volume":"30","author":"J Du","year":"2019","unstructured":"Du J. Upregulation of sine oculis homeobox homolog 3 is associated with proliferation, invasion, migration, as well as poor prognosis of esophageal cancer. Anticancer Drugs. 2019;30(6):596.","journal-title":"Anticancer Drugs"},{"issue":"11","key":"3636_CR56","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41417-022-00488-9","volume":"29","author":"TL Ma","year":"2022","unstructured":"Ma TL, Zhu P, Chen JX, Hu YH, Xie J. SIX3 function in cancer: progression and comprehensive analysis. Cancer Gene Ther. 2022;29(11):1542\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3636_CR57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12885-022-09602-4","volume":"22","author":"H Wen","year":"2022","unstructured":"Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. BMC Cancer. 2022;22(1):550.","journal-title":"BMC Cancer"},{"issue":"2","key":"3636_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.20892\/j.issn.2095-3941.2022.0525","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang X, Du F, Yue J, Si Y, Zhao X, et al. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer. Cancer Biol Med. 2023;20(2):155\u201368.","journal-title":"Cancer Biol Med"},{"issue":"12","key":"3636_CR59","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1158\/1055-9965.EPI-22-0590","volume":"31","author":"A Walens","year":"2022","unstructured":"Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, et al. RNA-Based classification of homologous recombination deficiency in Racially diverse patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(12):2136\u201347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"3636_CR60","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","volume":"73","author":"X Zhang","year":"2013","unstructured":"Zhang X, Claerhout S, Pratt A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically Stable, biologically and ethnically Diverse, Patient-derived human breast cancer xenograft (PDX) models. Cancer Res. 2013;73(15):4885\u201397.","journal-title":"Cancer Res"},{"issue":"12","key":"3636_CR61","doi-asserted-by":"publisher","first-page":"101834","DOI":"10.1016\/j.xcrm.2024.101834","volume":"5","author":"S Awasthi","year":"2024","unstructured":"Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, et al. UBA1 Inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024;5(12):101834.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3636_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-021-01516-5","volume":"126","author":"M Mondal","year":"2022","unstructured":"Mondal M, Conole D, Nautiyal J, Tate EW. UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology. Br J Cancer. 2022;126(1):24\u201333.","journal-title":"Br J Cancer"},{"key":"3636_CR63","doi-asserted-by":"crossref","unstructured":"Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A et al. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol. 2024;14. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2024.1362641\/full.","DOI":"10.3389\/fonc.2024.1362641"},{"issue":"7","key":"3636_CR64","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","volume":"27","author":"S Wahby","year":"2021","unstructured":"Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(7):1850\u20134.","journal-title":"Clin Cancer Res"},{"key":"3636_CR65","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.1016\/j.annonc.2020.08.460","volume":"131","author":"A Bardia","year":"2020","unstructured":"Bardia A, Spring LM, Juric D, Partridge A, Ligibel J, Kuter I, et al. 358TiP phase Ib\/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer. Ann Oncol. 2020;131:S394.","journal-title":"Ann Oncol"},{"issue":"7","key":"3636_CR66","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive genomic analysis identifies novel subtypes and targets of Triple-Negative breast cancer. Clin Cancer Res. 2015;21(7):1688\u201398.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3636_CR67","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","volume":"29","author":"Y Bareche","year":"2018","unstructured":"Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29(4):895\u2013902.","journal-title":"Ann Oncol"},{"issue":"1","key":"3636_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41523-021-00363-0","volume":"7","author":"I Mavrommati","year":"2021","unstructured":"Mavrommati I, Johnson F, Echeverria GV, Natrajan R. Subclonal heterogeneity and evolution in breast cancer. NPJ Breast Cancer. 2021;7(1):155.","journal-title":"NPJ Breast Cancer"},{"issue":"7035","key":"3636_CR69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"6","key":"3636_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1\/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3636_CR71","doi-asserted-by":"publisher","first-page":"12105","DOI":"10.1038\/ncomms12105","volume":"7","author":"Y Gao","year":"2016","unstructured":"Gao Y, Mutter-Rottmayer E, Greenwalt AM, Goldfarb D, Yan F, Yang Y, et al. A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis. Nat Commun. 2016;7(1):12105.","journal-title":"Nat Commun"},{"issue":"1","key":"3636_CR72","doi-asserted-by":"publisher","first-page":"15304","DOI":"10.1038\/s41598-018-33601-w","volume":"8","author":"Y Gao","year":"2018","unstructured":"Gao Y, Kardos J, Yang Y, Tamir TY, Mutter-Rottmayer E, Weissman B, et al. The Cancer\/Testes (CT) antigen HORMAD1 promotes homologous recombinational DNA repair and radioresistance in lung adenocarcinoma cells. Sci Rep. 2018;8(1):15304.","journal-title":"Sci Rep"},{"issue":"32","key":"3636_CR73","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1038\/s41388-022-02369-9","volume":"41","author":"D Tarantino","year":"2022","unstructured":"Tarantino D, Walker C, Weekes D, Pemberton H, Davidson K, Torga G, et al. Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene. 2022;41(32):3969\u201377.","journal-title":"Oncogene"},{"key":"3636_CR74","doi-asserted-by":"crossref","unstructured":"Zhao C, Yang Z, yi, Zhang J, Li O, Liu S, lei, Cai C, et al. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53\/mTOR pathway. J Transl Med. 2022;30(1):434.","DOI":"10.1186\/s12967-022-03635-w"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03636-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:02:41Z","timestamp":1774886561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03636-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3636"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03636-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University (VCU) gave its approval for studies involving mice (Protocol# AD10001247) and all experiments were carried out in compliance with IACUC rules and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}